Search Bar & Filters
Found 26 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying if the drugs abemaciclib and letrozole are effective and safe for people with advanced or recurrent estrogen receptor positive ER, mismatch repair proficient, TP53 wild-type endometrial cancer. This phase 2 trial specifically looks at maintenance treatment after initial chemotherapy with carboplatin and paclitaxel, with or without anti-PD-L1 therapy. The FDA has not approved these drugs for endometrial cancer, but they are approved for other uses. Participants will receive oral abemaciclib twice daily and letrozole once daily in 21-day cycles for up to 2 years. The treatment schedule involves continuous dosing with scans X-ray, CT, MRI, or PET every 9 weeks for the first 9 months, then annually. The study includes a baseline scan, regular treatment cycles, an end-of-treatment visit with assessments and scans, followed by a 3-year follow-up period. During the study, participants will have various scans and blood tests to monitor their cancer status and overall health. Electrocardiograms EKGs will also be conducted. Researchers will measure progression-free survival over up to 2 years as the main outcome, along with adverse event rates, overall survival up to 5 years, and response rates. Participants adherence to oral medication will be monitored, and safety will be followed closely throughout treatment and the extended follow-up period.
Actively Recruiting
Researchers are evaluating a new imaging approach for men with intermediate- or high-risk prostate cancer who plan to receive hormone therapy and radiation treatment. The study aims to see if using a special imaging test during hormone therapy can help doctors better identify where active cancer remains in the prostate. This could allow for more precise radiation targeting, potentially reducing side effects by avoiding unnecessary treatment to healthy areas. All participants will receive standard hormone therapy androgen deprivation therapy or ADT for about six months, combined with stereotactic body radiation therapy SBRT beginning around 10 weeks after starting ADT. Three PSMA PETCT scans and MRI scans will be performed before hormone therapy begins, about eight weeks after ADT starts before radiation planning, and at 24 weeks end of treatment. Based on these scans, some patients may receive an extra focused radiation boost to areas where active cancer remains, while others may not need this boost if the cancer has responded well. Participants will be monitored with imaging, blood tests measuring PSA levels, and patient-reported quality of life questionnaires focusing on urinary, bowel, and sexual symptoms. Researchers will assess how well the imaging guides radiation planning and treatment targeting. The total participation lasts about six months, during which standard treatments are combined with experimental imaging to improve radiation precision and reduce side effects for future patients.
Actively Recruiting
Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.
Actively Recruiting
Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.
Actively Recruiting
This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are studying glioblastoma GBM, a fast-growing brain cancer affecting older adults who have special medical and care needs. This trial explores whether giving higher radiation doses in fewer sessions dose-escalated hypofractionation can improve treatment outcomes compared to the standard shorter radiation course. The study is a phase 2 randomized trial aiming to compare safety and effectiveness of these two radiation schedules in people aged 65 and older with newly diagnosed GBM. Participants will receive radiation therapy for three weeks, either as a standard hypofractionated regimen or a dose-escalated hypofractionated regimen with higher daily radiation doses. Both approaches deliver fewer radiation treatments than traditional schedules but differ in daily dose intensity. The study randomly assigns patients to one of these two groups to assess which approach may offer better results. During the trial, participants undergo screening to confirm eligibility, receive radiation treatments, and have follow-up visits to track symptoms and side effects. Researchers will measure overall survival, progression-free survival, treatment-related side effects, quality of life, mood, geriatric assessments, and performance status over up to six months after enrollment. The study will monitor participants for about one year on average to evaluate the effects of the treatments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new blood test called the Circulating Tumor DNA ctDNA Assay to screen for Epidermal Growth Factor Receptor EGFR positive lung cancer among East Asian and Latinx adults aged 40 to 80 who are at risk but cannot undergo regular lung cancer screening. This test focuses on detecting specific EGFR gene changes that make up most EGFR mutations in lung cancer. The study aims to assess whether this blood test can identify lung cancer before symptoms appear. Participants provide blood samples that are tested using the investigational ctDNA assay. If the test shows positive or unclear results, further confirmation is done through CLIA testing, followed by a lung CT scan if confirmed. Depending on CT scan results, participants may receive referrals for additional evaluation or have repeat scans after 12 months. Optional activities include a one-time survey on lung cancer screening perceptions, virtual focus groups, and blood banking studies. During the study, participants undergo eligibility screening, blood sample collection, and complete a baseline questionnaire. They may also participate in optional surveys or focus groups. Researchers monitor detection rates of lung cancer over two years, turnaround time for test results, recruitment acceptability, and challenges in collecting samples. Participants will be informed of their results and followed accordingly, with the study expected to run until 2030.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are studying an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy GA, a condition where parts of the retina gradually stop working and vision worsens. The study aims to assess how safe and tolerable pozelimab is when used in this way. It also looks at side effects, how the drug moves through the blood and eye fluid, and whether the body produces antibodies that might affect the drugs action. Participants will receive intravitreal injections of pozelimab according to the study protocol. The study is organized in parts, with dose escalation and repeated doses being evaluated. Participants are randomly assigned in a quadruple-masked way to receive treatment. The study focuses on adults aged 50 years and older with GA linked to age-related macular degeneration AMD. During the trial, participants will have their vision tested and eye health monitored through visual acuity measures and assessments of adverse events in the eyes and body. Blood and eye fluid samples will be collected to measure drug levels and antibody responses up to 16 weeks. The main safety outcomes involve tracking treatment-emergent adverse events in the study eye and systemically during the 8 and 16 week periods. The total participation duration can last up to 16 weeks with regular evaluations.
1-10 of 26
1